RxDoctor Payments Data

Talat Khan, MD

Internal Medicine · Corona, CANPI 1992886337

Payments from drug & device makers

$1,300in general payments, 2019–2025

Across 65 payments — averaging $20.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$165
  • AstraZeneca$162
  • Abbott$135
  • Corcept Therapeutics$107
  • Amgen$90
  • Lilly USA, LLC$87
  • plus $553 from 14 others

What the payments were for

  • Food & beverage$1,29299%
  • Education$91%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,300 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$27,166
Medicare patients
87
Services billed
390

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide139$135,919
JanuviaSitagliptin Phosphate65$51,631
FarxigaDapagliflozin Propanediol70$51,396
TrulicityDulaglutide32$34,216
EliquisApixaban28$28,943
JardianceEmpagliflozin19$18,608
XareltoRivaroxaban14$11,970
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$9,192
LinzessLinaclotide17$8,913
DapagliflozinDapagliflozin Propanediol13$8,444
LyricaPregabalin12$7,142
Lantus SolostarInsulin Glargine,hum.Rec.Anlog43$5,614
Breo ElliptaFluticasone/Vilanterol11$4,116
Albuterol Sulfate HfaAlbuterol Sulfate105$3,583
Atorvastatin Calcium358$3,278

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$59$135,919139 claims
MerckJanuvia$56$51,63165 claims
AstraZenecaFarxiga$162$51,39670 claims
PfizerEliquis, Lyrica$62$36,08640 claims
Lilly USA, LLCTrulicity$87$34,21632 claims
Johnson & JohnsonXarelto$45$11,97014 claims
AbbVieLinzess$62$8,91317 claims
GSKBreo Ellipta$75$4,11611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Corona

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →